Kim et al. found that BRCA2 mutant-lung cancer organoids showed a good response to olaparib whereas EGFR mutant and EGFR-mutant/MET-amplified organoids showed better response to erlotinib and crizotinib, respectively [62]. This evidence concerns the gene MET and lung carcinoma.